JOHNSON & JOHNSON

For the period ended Dec 28, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

JNJ$285.75+0.8%Stored close · as of Nov 13, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of equity

Checking your notes…

Johnson & Johnson and subsidiaries consolidated statements of equity

Total · RetainedEarnings andAdditionalpaid-incapital · AccumulatedOtherComprehensiveIncome (Loss) · CommonStockIssuedAmount · TreasuryStockAmount
Balance, January 1, 2023	$76,804	128,345	(12,967)		3,120	(41,694)
Net earnings	35,153	35,153
Cash dividends paid ($4.70 per share)	(11,770)		(11,770)
Employee compensation and stock option plans	2,193	(336)				2,529
Repurchase of common stock	(5,054)					(5,054)
Other	(25)					(25)
Kenvue Separation /IPO (Note 21)	(23,786)		2,451		5,181		(31,418)
Other comprehensive income (loss), net of tax	(4,741)			(4,741)
Balance, December 31, 2023	68,774	153,843	(12,527)		3,120	(75,662)
Net earnings	14,066	14,066
Cash dividends paid ($4.91 per share)	(11,823)		(11,823)
Employee compensation and stock option plans	2,094	(295)				2,389
Repurchase of common stock	(2,407)					(2,407)
Other comprehensive income (loss), net of tax	786		786
Balance, December 29, 2024	71,490	155,791	(11,741)		3,120	(75,680)
Net earnings	26,804	26,804
Cash dividends paid ($5.14 per share)	(12,381)		(12,381)
Employee compensation and stock option plans	4,773	(1,236)				6,009
Repurchase of common stock	(5,953)					(5,953)
Other comprehensive income (loss), net of tax	(3,189)			(3,189)
Balance, December 28, 2025	$81,544	168,978	(14,930)		3,120	(75,624)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.